Corporate Governance

Hellerup – October 10, 2026 -- Christopher Boehringer has resigned from the Board of Directors of TORM plc (NASDAQ: TRMD, TRMD A) with immediate effect, after Oaktree Capital Management and its affiliates ceased to hold any ownership interest in the product tanker owner.

Boehringer leaves the board after eleven years of service

Boehringer joined the TORM board in 2015. TORM said he supported the company through a period of significant transformation and growth.

Chair Simon Mackenzie Smith credited him with helping to develop and strengthen the One TORM platform and called him a trusted adviser through some of the most important milestones in the company's history.

Five directors remain on the TORM board

Following the change, the board comprises Simon Mackenzie Smith (Chair), Annette Malm Justad, Göran Trapp, Jann Brown and Jacob Meldgaard.

TORM did not announce a replacement for Boehringer's seat.

Stockholm – – October 09, 2026 -- Boliden AB has appointed a Nomination Committee drawn from its three largest shareholders by voting rights, with Swedbank Robur Fonder's Lennart Francke as Chair, ahead of the 2027 Annual General Meeting on April 28, 2027.

Three institutional investors fill the committee seats based on the August 31 share register

Under instructions adopted by Boliden's Annual General Meeting, the committee consists of members appointed by the three largest shareholders by voting rights. Selection is based on Euroclear Nordics AB's print-out of the share register as of August 31, 2026, and is subject to each shareholder's willingness to participate.

• Lennart Francke, Swedbank Robur Fonder (Chair)
• Magnus Tell, Alecta
• Karin Eliasson, Handelsbanken Fonder

Board Chair Karl-Henrik Sundström has been co-opted to the committee.

Dallas – September 21, 2026 -- Solidion Technology, Inc. (NASDAQ: STI) has combined its Chairman and CEO roles, appointing Jaymes Winters to the dual position effective September 16, 2026, while naming Mark N. Schwartz as Lead Independent Director.

Winters adds Chairman title to CEO role effective September 16

Winters, who brings more than 15 years of chief executive experience across oil and gas, telecommunications and retail, will retain the CEO title while assuming board chairmanship. He previously served as CEO of Nubia Brand International Corp, a special purpose acquisition company, and founded United Energy Inc., which he grew to nearly $100 million in revenue. Winters also taught business strategy, mergers and acquisitions, and venture capital for more than 9 years as an adjunct professor at Portland State University's School of Business.

San Rafael, Calif. – September 18, 2026 -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) has appointed Robert Plenge, M.D., Ph.D., to its Board of Directors, effective September 18, 2026.

Plenge brings nine-site global research oversight from Bristol Myers Squibb

Dr. Plenge currently serves as Executive Vice President, Chief Research Officer and Head of Research at Bristol Myers Squibb, directing scientific operations across nine research sites worldwide. He joined the company in November 2019 through its acquisition of Celgene Corp., where he had led the immunology and inflammation portfolio in research and early development.